Back to all events

Evaluating Science through the Lens of Commercialization


Mar 08 2024, Friday04:00 PM - 07:00 PM (GMT +8:00) Kuala Lumpur, Singapore


The Masons Table, 23A Coleman St, Singapore, 179806

, Singapore



This event will revolve around strategies and considerations taken when evaluating innovative projects from a commercialization perspective. We will discuss the approaches that key Pharmaceutical MNCs and investors take when deciding whom to invest in, partner with, or collaborate with, and how they integrate these methodologies to formulate their 'wish-list'.


Date: 08 Mar 2024, Friday
Time: 4:00 PM - 7:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: The Masons Table, 23A Coleman St, Singapore, 179806


Speaker's Profile:

Dr Nikhil Mutyal, Executive Director, Business Development and Licensing (BD&L), MSD
Dr Nikhil Mutyal

Nikhil joined MSD in January 2020 and is currently based at the Company’s South San Francisco site. As a member of the Pacific Site team, Nikhil leads the Company’s search and evaluation efforts for BD&L opportunities from companies and research institutes located in the West Coast of North America, Singapore, India, Australia and New Zealand. Nikhil is the overall lead for such BD&L opportunities in the areas of Oncology, Neuroscience, and Cardiometabolic Diseases. Nikhil's expertise in strategic licensing and M&A spans over a decade, and he has successfully built a professional career that had spanned across management consulting for pharma/biotech and BD roles across various companies. Nikhil's educational background includes a Ph.D. in Biomedical Engineering with a focus on cancer research from Northwestern University. Prior to that, he obtained his B.S. and M.S. degrees in Medicinal Chemistry from Indian Institute of Technology (IIT) Kanpur.

Speaker's Profile:

Navjeewan J. Khosla, Partner, Novo Holdings Equity Asia
Navjeewan J. Khosla

Nav joined Novo Holdings Asia in August 2021. He focusses on deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia. Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and South East Asia. Before joining Quadria Capital, Nav was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun. Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian Institute of Technology (IIT), Kharagpur in India.

Speaker's Profile:

Miemie Strydom, Director New Business Development, JOHNSON & JOHNSON INNOVATIVE MEDICINE ASIA PACIFIC
Miemie Strydom

Miemie is an active healthcare investor/advisor and business development executive with more than 15 years industry experience in both advisory capacity (Deutsche Bank, IQVIA), and “in-house” as member of management teams (DaVita, Reckitt Benckiser, Indivior, Hummingbird Bioscience, J&J) across various industry verticals including Pharma, Medtech and Biotech. Trained as a medical scientist, she holds a Bachelor’s degree in Medical Sciences and an MBA from London Business School In her current role at J&J, she owns commercial viability assessments and end-to-end deal execution for external investment cases in Immunology and Haematology for Asia Pacific. Passionate about enabling investments and community building, she continues working with and mentoring healthcare startups on fundraising, strategy and commercial Go-To-Market readiness as investor/advisor. She also dedicates her personal time to a variety of charitable organizations, such as Singapore Red Cross & United Women Singapore.

Moderator's Profile:

Dr Lim Jui, CEO, SG Innovate
Dr Lim Jui

As CEO of SGInnovate, Dr Lim Jui and his team work closely with a wide range of partners and co-investors to back Deep Tech startup founders, who are looking to solve global challenges with their research-based solutions. While he trained in medicine, Jui spent most of his professional life in the business of science and innovation. He was Director of Investments, Bio*One Capital; CEO of Merlin MD, a medical device company; Executive Director of the Medical Engineering Research and Commercialisation Initiative (MERCI) at the National University of Singapore (NUS); and Programme Director of the Singapore-Stanford Biodesign Programme (SSB), a joint venture between A*STAR, the Singapore Economic Development Board (EDB) and Stanford University. Before joining SGInnovate, Jui was CEO of NTUitive, the innovation and enterprise company of the Nanyang Technological University (NTU). He currently serves on the advisory boards of IPOS International and several start-up companies.